---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-002430"
form_type: "8-K"
ticker: "SMNR"
cik: "0001913577"
company_name: "Semnur Pharmaceuticals, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T01:06:39.554691+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Denali Capital shareholders approve merger with Longevity Biomedical; 4.44M shares redeemed

## Summary
- Shareholders approved all proposals: Business Combination, Merger, Share Capital, Organizational Documents, Governance, and Incentive Plan.
- Approximately 4,440,202 public shares redeemed from trust account after withdrawals, ahead of closing.
- Adjornment proposal not needed as sufficient votes secured for all other proposals.
- Company plans to close the Business Combination as detailed in the proxy statement.

## SEC filing metadata
- accession: 0001213900-24-002430
- form_type: 8-K
- ticker: SMNR
- cik: 0001913577
- company_name: Semnur Pharmaceuticals, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1913577/000121390024002430/0001213900-24-002430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1913577/000121390024002430/ea191397-8k_denalicap.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-002430
- JSON: https://secwatch.observer/filing/0001213900-24-002430.json
- Plain text: https://secwatch.observer/filing/0001213900-24-002430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.